

Topical Collection

Prostate Cancer: Pathophysiology, Pathology and Therapy

Message from the Collection Editor

Prostate cancer is a major healthcare challenge in the developed world and represents the second most common cause of cancer death in men. A remarkable heterogeneity is noted in its clinical course. Some patients have indolent cancer that will never progress, whereas others have remarkably aggressive disease with rapid progression to metastases and resistance to therapy. In between are patients with initially localized disease that will progress to metastatic incurable disease after a variable time period. The clinical heterogeneity of prostate cancer is a reflection of its molecular heterogeneity and the emergence of lineage plasticity. Recent research has provided significant advances in the understanding of the molecular, genomic and epigenetic features of prostate cancer and, as a result, multiple therapeutic options have been added to our armamentarium. In addition, potential new therapeutic targets have been identified and are being tested in preclinical and clinical studies.

Collection Editor

Dr. Vasiliki Tzelepi

Department of Pathology, School of Medicine, University of Patras,
Patras, Greece



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/61278

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)